Upadacitinib, RoActemra 162 mg solution for injection in pre-filled syringe., RoActemra 162 mg solution for injection in pre-filled pen., Upadacitinib, RoActemra 20 mg/mL concentrate for solution for infusion
M14-682
Phase 3 small_molecule active
Quick answer
Upadacitinib, RoActemra 162 mg solution for injection in pre-filled syringe., RoActemra 162 mg solution for injection in pre-filled pen., Upadacitinib, RoActemra 20 mg/mL concentrate for solution for infusion for juvenile idiopathic arthritis is a Phase 3 program (small_molecule) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AbbVie Deutschland GmbH & Co. KG
- Indication
- juvenile idiopathic arthritis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active